New treatments for Merkel cell carcinoma
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment
This research looks for new ways to treat Merkel cell carcinoma, a serious skin cancer, especially for patients who don't respond to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Southern California Inst for Res/educ NIH-funded |
| Lab location | 1 site (Long Beach, UNITED STATES) |
| Project ID | NIH-11123323 on NIH RePORTER |
What this research studies
Merkel cell carcinoma is a very aggressive skin cancer with limited treatment options and a low survival rate for advanced cases. While immune checkpoint inhibitors are a standard treatment, many patients are not eligible or develop resistance, leaving them with no other choices. This project aims to find new therapies that can either boost the effectiveness of current treatments, overcome resistance, or serve as alternatives for those who cannot use existing drugs. Researchers are testing a new drug called fimepinostat, alone and in combination with immune checkpoint inhibitors, to see how well it works and how it affects cancer cells and their surroundings.
Who could benefit from this research
Good fit: Patients with Merkel cell carcinoma, particularly those who do not respond to current immune therapies or are ineligible for them, could benefit from future treatments developed from this research.
Not a fit: Patients without Merkel cell carcinoma would not directly benefit from this specific research, as it focuses on this particular cancer.
Why it matters
Potential benefit: If successful, this work could lead to new and more effective treatment options for patients with Merkel cell carcinoma, potentially improving survival rates and quality of life.
How similar studies have performed: Initial laboratory screening has identified fimepinostat as a promising drug with strong anti-cancer activity against Merkel cell carcinoma cells.
Where this research is happening
Long Beach, UNITED STATES
- Southern California Inst for Res/educ — Long Beach, United States (Active)
Researchers
- Principal investigator: Gao, Ling — Southern California Inst for Res/educ
- Study coordinator: Gao, Ling
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.